X0306 4 2019-06-19 0 0001098972 AGENUS INC AGEN 0000935679 ARMEN GARO H 3 FORBES ROAD LEXINGTON MA 02421 1 1 0 0 Chairman and CEO Common Stock 2020-04-24 4 A 0 5296 2.79 A 1112282 D Common Stock 163046 I See footnote. Stock Option (Right to buy) 2.38 2019-06-19 4 A 0 42500 0 A 2028-12-31 Common Stock 42500 42500 D As previously reported in Current Report on Form 8-K filed with the Securities and Exchange Commission on March 30, 2020, Garo H. Armen's salary is being paid in stock, in lieu of cash, for the balance of 2020. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending April 24, 2020. Such shares are issued in accordance with the Agenus Inc. 2019 Equity Incentive Plan and are fully vested on the date of issuance. $2.79 is the closing price of our Common Stock on April 24, 2020, the payroll date for the pay period ending April 24, 2020. Dr. Armen is trustee and has investment authority for the Garo Armen 2018 2 Year AG GRAT holder of 159,000 shares of Agenus common stock. Dr. Armen is Chairman of the Board of Managers and a member of Antigenics, LLC ("Antigenics") which as of the date of this report owns 4,046 of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Antigenics and disclaims beneficial ownership to the extent of his pecuniary interest therein. Option granted on December 31, 2018, subject to shareholder approval, which was obtained at Agenus Inc.'s annual shareholder meeting on June 19, 2019. Option awarded in accordance with Agenus Inc. 2009 Amended and Restated Equity Incentive Plan and one third of the option vested on January 1, 2020 and the balance will vest in equal quarterly installments thereafter; provided, however, that the unvested portion of such option shall vest in full upon Dr. Armen's death, disability or retirement. /s/Evan D. Kearns, as Attorney-in-Fact for Garo H. Armen 2020-04-24